Get the Stockscreener App
7.515
2.44%
0.135
Immunitybio Inc stock is traded at $7.515, with a volume of 5.75M.
It is up +2.44% in the last 24 hours and down -22.70% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.38
Open:
$7.37
24h Volume:
5.75M
Relative Volume:
0.16
Market Cap:
$7.72B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-19.28
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-10.74%
1M Performance:
-22.70%
6M Performance:
+197.63%
1Y Performance:
+125.00%
1-Day Range:
$7.13
$7.58
1-Week Range:
$6.54
$9.54
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.51 | 7.59B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
445.80 | 115.27B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.10 | 80.00B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
695.13 | 43.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
324.70 | 43.52B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
286.86 | 30.74B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? - Zacks Investment Research
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 - BioSpace
Rosen Law Firm Files Securities Class Action Lawsuit Against ImmunityBio - National Today
Robbins LLP Informs Investors of ImmunityBio Class Action Lawsuit - National Today
Investor Notice: Robbins LLP Informs Investors of the ImmunityBio, Inc. Class Action Lawsuit - PharmiWeb.com
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Kyndryl Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KD - GlobeNewswire Inc.
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of ImmunityBio, Inc. Investors – IBRX - The AI Journal
Kaplan Fox Announces an Investigation Into ImmunityBio, Inc. (IBRX) for Possible Securities Law Violations - NewMediaWire
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
ImmunityBio Confirms Trial Strength For Anktiva In Bladder Cancer - Stocktwits
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio, Inc. announced that its pivotal randomized BCG-naive non-muscle invasive bladder cancer (NMIBC) trial has demonstrated sufficient statistical power to detect clinically meaningful differences between the Anktiva® plus BCG treatment regimen a - Bitget
ImmunityBio bladder cancer trial deemed adequately powered by IDMC - Investing.com
FDA Warning Puts ImmunityBio Anktiva Hopes And Valuation In Focus - Yahoo Finance
IBRX SEC FilingsImmunitybio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
FDA Warns ImmunityBio Over Misleading Cancer Drug Claims - National Today
Why ImmunityBio Stock Is Up More Than 11% Today - AOL.com
Soon-Shiong’s Drug Deception - status.news
IBRX Stock Is Back: Anktiva Now Targets Severe Pneumonia After Clearing Key Checkpoint In Bladder Cancer Trial - Stocktwits
FDA Warning On Anktiva Puts ImmunityBio Growth Story Under Scrutiny - simplywall.st
ImmunityBio (NASDAQ:IBRX) Trading Up 8.9%Still a Buy? - MarketBeat
FDA Objects to Claims by Soon-Shiong on Cancer Drug - newser.com
FDA Issues Warning Letter to ImmunityBio | PharmExec - Pharmaceutical Executive
Why the FDA flagged ImmunityBio’s ‘false and misleading’ claims in podcast, TV spot - Medical Marketing and Media
ImmunityBio’s Global Expansion Raises Stock Speculation - timothysykes.com
Why Is ImmunityBio (IBRX) Down 35.8% Since Last Earnings Report? - Yahoo Finance
ImmunityBio Inc. (IBRX) Announces Approval for ANKTIVA® in Macau SAR, China - Yahoo Finance
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement - Pharmaceutical Executive
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims - TradingView
IBRX stock still a buy after worst day in over a year? Why this analyst is shrugging off FDA warning letter - MSN
FDA warns manufacturer that billionaire's claims about cancer drug Anktiva are misleading - CBS News
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRX - The National Law Review
Kaplan Fox Investigating ImmunityBio for Potential Securities Violations - National Today
Kaplan Fox is Investigating ImmunityBio, Inc. (IBRX) for Potential Securities Law Violations - The National Law Review
FDA slams Soon-Shiong and ImmunityBio for making 'false and misleading' claims about a drug - statnews.com
FDA Issues Warning Letter to ImmunityBio Over 'False and Misleading' Claims for Bladder Cancer Drug Anktiva - drugscontrol.org
Drugmaker’s stock tumbles 20% after FDA issues formal warning to executives - HealthExec
Biopharma bites: ImmunityBio's 'misleading' ad, UCB's manufacturing hub, plus Aardvark's obesity pause - FirstWord Pharma
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad - Reuters
ImmunityBio (NASDAQ:IBRX) Trading Down 21.1%Time to Sell? - MarketBeat
FDA flags misleading claims for cancer drug by biotech billionaire Patrick Soon-Shiong - KIRO 7 News Seattle
BTIG reiterates Immunitybio stock Buy rating after FDA warning By Investing.com - Investing.com South Africa
Immunitybio Inc.Bio, News, Photos - Washington Times
Is ImmunityBio (IBRX) Still Attractive After A 365% Year To Date Surge - simplywall.st
Key facts: ImmunityBio $113M 2025 revenue; FDA questions ANKTIVA - TradingView
ImmunityBio Gains on Anktiva Approval in Macau, First in Asia | 2026News and Statistics - IndexBox
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):